Mendelspod Podcast

Chapters: 0:00   State of the field: reviewing ICoNS conference 22:20 What evidence is enough? Today, we’re joined by a panel of four guests who have all attended the recent International Conference on Newborn Sequencing held at the Royal Institution in London.  This discussion serves as the second part in a series we are co-producing with GenomeWeb that began with last month’s panel.  At the conf...

This is a free preview of a paid episode. To hear more, visit www.mendelspod.com Chapters:0:00 Precision oncology is standard of care13:50 Culmination Bio23:25 Hopeful about early cancer screening25:45 Biggest challenge for the field? When Lincoln Nadauld began Precision Genomics at Utah-based Intermountain Healthcare, he told the administrators that precision oncology is coming and will be standa...

This is a free preview of a paid episode. To hear more, visit www.mendelspod.com Chapters:0:00 What are transcription factors?7:00 The MARMOT platform11:22 In the ’90s, people thought kinases were undruggable19:00 Where’s the company at today? We begin today’s show with definitions.  What are transcription factors?  What is functional proteomics?  And what is meant by “undruggable?"According to a...

This is a free preview of a paid episode. To hear more, visit www.mendelspod.com Chapters:0:00 Attending this year’s Human Proteome Organization (HUPO) conference4:40 Mass spec vs. sequencing8:12 How does the Orbitrap Astral fit into the market?12:55 Customer applications Thermo Fisher Scientific is a name synonymous with life science tools.  They have been at the vanguard of every important trend...

This is a free preview of a paid episode. To hear more, visit www.mendelspod.com Chapters:0:00 What does treatment look like?7:25 Light treatment has been approved for years20:10 Could this be a primary therapy for all cancers?25:05 Challenges? We often cover new therapies for cancer.  They are usually derived from “chemistry."  But what about using “physics” in a non-invasive way for treatment? ...

Chapters:0:00  “It’s a magical time.”9:55 Tracking low-concentration proteins in real-time19:20 What next?24:40 Proteins act in community29:30 Challenges ahead? Many new drugs and clinical diagnostics are being derived from proteins. Today we take our proteomics series into the clinic with Jenny Van Eyk from Cedars Sinai Hospital in Los Angeles and Daniel Hornburg of the proteomics company, Seer. ...

Today’s show is made free by the generous support of Twist Bioscience. Twist works in service of people changing the world for the better in fields such as medicine, agriculture, industrial chemicals, and data storage. Their unique silicon-based DNA synthesis platform provides precision that is otherwise unavailable. Check out their products at www.twistbioscience.com. And join them as they write...

This is a free preview of a paid episode. To hear more, visit www.mendelspod.com Chapters: 0:00 World’s longest oligo 8:45 Why is it difficult to synthesize long DNA? 12:00 Proprietary TdT conjugate 16:00 A billion-dollar market 24:20 The computation model and its challenges 28:35 More customers using generative AI Mendelspod is now reader supported. Please consider upgrading to a paid subscriptio...

This is a free preview of a paid episode. To hear more, visit www.mendelspod.com Chapters:0:00 Novel Cas enzymes help overcome CRISPR challenges11:37 New pipeline of therapies will go after novel targets14:52 How does the new platform open up possibilities for new diagnostics?21:05 What risks do you think about?26:47 What are the company’s two-year goals?31:07 On the possibilitiesCRISPR technology...

This is a free preview of a paid episode. To hear more, visit www.mendelspod.com 0:00 Latest paper on multi-omics microsampling6:30 Is it useful?  Two scenarios13:00 How might entrepreneurs bring this to healthcare?18:15 How do you convince physicians?25:48 Are you a reductionist?31:00 Impact of generative AI38:15 Thoughts on the renaissance in proteomics We open our 13th season here at Mendelspod...

Ten years ago this week, the Supreme Court unanimously ruled that genes could not be patented. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

Today we feature Quantum-SI, one of the new wave of proteomics tools companies.  The company was founded by serial life science entrepreneur, Jonathan Rothberg, originally as a long read sequencing company.    Though the company pivoted to proteomics, they kept the sequencing part. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit...

SynBioBeta is the largest gathering of the synthetic biology community worldwide.  It’s taking place May 23-25 in Oakland, California.  John Cumbers is the founder and CEO of the conference, and he joins us to talk about trends in the space and preview this year’s confab. First, we discuss the impact Washington D.C. is having on the field.  What doe’s Biden’s love for bio mean for synbio? This is...

It’s a thrilling time to be in proteomics.  Today we discuss a recent paper in PLOS One demonstrating how new technology has revealed a novel biomarker for non-small cell lung cancer previously undetected by other methods.  The paper could be a model for new proteomics research going forward.  Our guests are Margaret Donovan, Product Marketing Manager, and Asim Siddiqui, Senior VP of Research, bot...

Philosophers talk about various kinds of knowledge.  There is knowing that something is.  We learn that the sun is 90 million miles from the Earth.  There is also knowing how to do something.  This includes skills we learn like riding a bike or cooking spaghetti.  Knowing how is different from knowing that. This is a public episode. If you'd like to discuss this with other subscribers or get acces...

Long DNA has arrived.   Elegen, a new company based in San Carlos, California,  is out this year offering just long DNA.  According to their founder and CEO, Matt Hill and today's guest, the company’s product is twenty times more accurate than anything else presently available. What does this mean for the world of biology and the world in general that we're seeing the emergence of a new subindustr...

"We’re not a sequencing company," says Molly He, CEO and co-founder of Element Biosciences in our first interview with the leader of the hot new sequencing company which seemed to come out of nowhere this past year. “We’re a biology company.” Not a sequencing company? Element has just taken the lead in the race toward cheap clinical genomes, and their CEO is putting that news aside in today’s inte...

Biology is complex, and the life science tool kit continues to expand to meet the challenge of that complexity taking us into the world of multi omics and beyond. Today we talk about 3D genomics and what this additional three-dimensional structural information is telling not just researchers, but clinicians, particularly in oncology. This is a public episode. If you'd like to discuss this with oth...

Today we talk with Simon Fredriksson, CEO and co-founder of Pixelgen Technologies, a company just out of stealth offering spatial technology that maps cellular surface proteins at the single cell level. Called molecular pixelation, the breakthrough technology is designed to first target immune cells. This is a public episode. If you'd like to discuss this with other subscribers or get access to bo...

Editor's Note: Theral's mic malfunctioned in this interview. Fortunately the not as good backup mic did work and John has a good mic.  Our apologies. John Greally joins us today. He is the founding Director of the Albert Einstein College of Medicine’s Center for Epigenomics. He’s a pediatrician and a clinical geneticist with appointments in both at Einstein. This is a public episode. If you'd like...

Last month the American Society of Human Genetics (ASHG) took a quite remarkable step, putting out a formal statement of apology for its past history of involvement with eugenics. Some say it’s long overdue while some of us didn’t know about this history. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscri...

23andMe occupies its own place in the world of genomics. Known for its vision to democratize human genomic information, the company has always gone big and bold, and sometimes controversial. Today we don’t hear much controversy—is that because their approach has won out? In any case, they have certainly achieved a scale that surpasses any other genetic testing company. This is a public episode. If...

Remember all those firsts for synthetic biology that we heard about coming from Craig Venter’s company, Synthetic Genomics in San Diego? The first genome of a whole organism transplanted. First genome synthesized. First synthetic life created. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

Oncology has emerged as the most successful disease area for precision medicine. Last year, as the genetic testing industry went through a royal shake-up brought on mostly by external market forces, it's been no surprise that precision oncology has been touted as a core strength. As the industry now works "to be more lean and profitable"--new language one hears these days, cancer testing will be a...

To begin the year, we head across the pond for an outlook on the thriving community of synthetic biology in the United Kingdom. Paul Freemont was a co-author of the UK's synthetic biology roadmap and co-directs SynbiCITE, the national center for the commercialization of synthetic biology. A few years ago the government put an initial investment of $300 million pounds into the field, and "everythin...